Combined CAR-T Congress Europe | Kisaco Research
A Collaborative Approach to Maximise the Potential of CAR-T
Berlin, Germany
30-31 January, 2018
Download Agenda
The Audience
Register

The Agenda

Download the Agenda

80+
Attendees
50:50
ratio of Academia to Industry
20+
Speakers
9+
Hours of Networking

Why Attend

Combined CAR-T Congress Europe gathers thought leaders from biotech, big pharma, academia and the wider service community to address the challenges and opportunities of CAR-T therapies – including CAR-T, CAR-Tregs and combined therapies - that are critical to furthering the development of viable T-cell therapies.

Exploring ground-breaking developments in this fast growing field, the event will provide the opportunity to collaborate to create a commercially viable, effective and safe therapy.  

Key session topics include:

  • Advancements in CAR-T manufacturing and automation
  • A combined approach to cell therapy
  • Results from unpublished human and clinical studies
  • Commercialisation of CAR-T therapies
  • Improving the safety of CAR-T through safety switches
  • Exploring the tumour microenvironment for therapy targets and improvements
  • The potential of CAR-Tregs in autoimmunity

Join us for a rare opportunity to hear first-hand from those with case studies on real patients and insight on solid tumours. Get involved today.

Innovation Showcase

Submit innovation showcase application

The Speakers

 

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

Dr David Sourdive, PhD

Executive Vice President Technical Operations
Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive holds the position of Executive Vice President, Technical Operations, with the mission to develop the Company’s industrial and technological basis as well as to deploy its operations in the pharmaceutical arena. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016.

 

Michaela Sharpe, PhD

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell and Gene Therapy Catapult

Michaela Sharpe is the Head of Nonclinical Safety and Immunotherapy Strategy at the Cell and Gene Therapy Catapult. Michaela has over fifteen years’ experience in the Pharmaceutical Industry both in the biotechnology sector and large pharma where she has specialised in the nonclinical development of cell based therapies and therapeutic vaccines. She was Head of the Stem Cell Safety Group at Pfizer and prior to joining the Catapult she ran her own consultancy business.

Michaela Sharpe, PhD

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell and Gene Therapy Catapult

Michaela Sharpe is the Head of Nonclinical Safety and Immunotherapy Strategy at the Cell and Gene Therapy Catapult. Michaela has over fifteen years’ experience in the Pharmaceutical Industry both in the biotechnology sector and large pharma where she has specialised in the nonclinical development of cell based therapies and therapeutic vaccines. She was Head of the Stem Cell Safety Group at Pfizer and prior to joining the Catapult she ran her own consultancy business.

 

Professor Ulrike Koehl

Director Institute of Cellular Therapeutics
Hannover Medical School, Germany

Ulrike Köhl is a full professor and director of the Institute of Cellular Therapeutics at Medical School Hannover, Germany. Previously she worked at MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. All her goals are focused on the development and manufacturing of cell-based therapies including Advanced Therapy Medicinal Products (ATMPs) and the improvement of cell processing strategies. She has a specific focus on primary human NK cells including chimeric antigen receptors (CAR) expressing NK cells.

Professor Ulrike Koehl

Director Institute of Cellular Therapeutics
Hannover Medical School, Germany

Ulrike Köhl is a full professor and director of the Institute of Cellular Therapeutics at Medical School Hannover, Germany. Previously she worked at MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. All her goals are focused on the development and manufacturing of cell-based therapies including Advanced Therapy Medicinal Products (ATMPs) and the improvement of cell processing strategies. She has a specific focus on primary human NK cells including chimeric antigen receptors (CAR) expressing NK cells.

 

Claudia Zylberberg, PhD

CEO
Akron Biotech

Claudia Zylberberg, PhD

CEO
Akron Biotech
 

Marco Ruella

Clinical Instructor & Associate Director Dr. Carl June’s Laboratory
Perelman School of Medicine, University of Pennsylvania

Marco Ruella

Clinical Instructor & Associate Director Dr. Carl June’s Laboratory
Perelman School of Medicine, University of Pennsylvania
 

Gareth Thomas

University of Southampton

Gareth Thomas

University of Southampton
 

Dr Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Career

present

Chief Scientific Officer at Cellex Patient Treatment GmbH

2013 - 2014

 

Post-Doc., Institute of Radiopharmaceutical Cancer Research Dep. Radioimmunology, Helmholtz Zentrum Dresden Rossendorf, Germany

2005 - 2013

Post-Doc., Institute of Immunology, TU Dresden, Germany

 

Education

2000 - 2005

Dr Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Career

present

Chief Scientific Officer at Cellex Patient Treatment GmbH

2013 - 2014

 

Post-Doc., Institute of Radiopharmaceutical Cancer Research Dep. Radioimmunology, Helmholtz Zentrum Dresden Rossendorf, Germany

2005 - 2013

Post-Doc., Institute of Immunology, TU Dresden, Germany

 

Education

2000 - 2005

 

Dr Stephen Miller

Director
Interdepartmental Immunobiology Center

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago.  He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center.  Dr.

Dr Stephen Miller

Director
Interdepartmental Immunobiology Center

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago.  He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center.  Dr.

 

Professor Hinrich Abken

Professor of Cancer Genetics, Internal Medicine
University Hospital of Cologne

Professor Hinrich Abken

Professor of Cancer Genetics, Internal Medicine
University Hospital of Cologne
 

Professor Andrew Sewell

Cardiff University

Andy Sewell’s research interests have focused around how organisms deal with environmental adversity. He began his career at the University of Liverpool by applying his training in chemistry towards phytoremediation strategies. He then moved to the University of Utah in 1990 to work on gene activation by environmental stress and was promoted to the Faculty there in 1994. Tugged heartstrings saw him return to Oxford in 1995 to work on the strategies HIV and other viruses use to subvert human T-cell immunity.

Professor Andrew Sewell

Cardiff University

Andy Sewell’s research interests have focused around how organisms deal with environmental adversity. He began his career at the University of Liverpool by applying his training in chemistry towards phytoremediation strategies. He then moved to the University of Utah in 1990 to work on gene activation by environmental stress and was promoted to the Faculty there in 1994. Tugged heartstrings saw him return to Oxford in 1995 to work on the strategies HIV and other viruses use to subvert human T-cell immunity.

 

Lynsey Whilding

CAR Mechanics Group
Kings College London

Dr Lynsey Whilding is a postdoctoral research associate with nearly 10 years experience in cell and gene therapy. She currently works in the “CAR Mechanics” research group at King’s College London and is a consultant for the biotechnology company Leucid Bio. Lynsey undertook a PhD in viral gene therapy at the Barts Cancer Institute within Queen Mary University from 2008-2012. She then started a research position at Imperial College and moved to King’s College London in 2014 to continue developing chimeric antigen receptor T-cells for the treatment of solid tumours.

Lynsey Whilding

CAR Mechanics Group
Kings College London

Dr Lynsey Whilding is a postdoctoral research associate with nearly 10 years experience in cell and gene therapy. She currently works in the “CAR Mechanics” research group at King’s College London and is a consultant for the biotechnology company Leucid Bio. Lynsey undertook a PhD in viral gene therapy at the Barts Cancer Institute within Queen Mary University from 2008-2012. She then started a research position at Imperial College and moved to King’s College London in 2014 to continue developing chimeric antigen receptor T-cells for the treatment of solid tumours.

 

Dr Sophie Papa

National Institute of Health Research Academic in Medical Oncology
Kings College London

Sophie Papa is a Senior Lecturer and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology.

Dr Sophie Papa

National Institute of Health Research Academic in Medical Oncology
Kings College London

Sophie Papa is a Senior Lecturer and Consultant Medical Oncologist at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. Sophie undertook her medical training at the University of Oxford and Imperial College London. She completed a PhD in cancer immunotherapy from King’s College London in 2011. She is a clinical academic with research interests in the field of immune-oncology.

 

Francois Meyer

CEO
TxCell

Francois Meyer

CEO
TxCell
 

Professor Elmar Jaeckel

Medizinische Hochschule Hannover

Professor Elmar Jaeckel

Medizinische Hochschule Hannover
 

Judy Gugenheim

Research Professor of Microbiology-Immunology
Northwestern Medical School

Judy Gugenheim

Research Professor of Microbiology-Immunology
Northwestern Medical School
 

Stefano Baila

Holding F.I.S

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT.  Stefano also worked  as Industrialization Manager at Celyad where he led process developmen

Stefano Baila

Holding F.I.S

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal products through business development and strategic marketing roles at Areta International, a CDMO, and by leading field implementation and commercialization activities for the cell processing unit of Terumo BCT.  Stefano also worked  as Industrialization Manager at Celyad where he led process developmen

 

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S.

Peter Emtage

Cell Design Labs

Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Labs, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S.

 

Luis Álvarez-Vallina

Associate Professor, Department of Molecular Engineering
Aarhus University

Luis Álvarez-Vallina, MD, PhD. Associate Professor at the Department of Engineering, Immunotherapy and Cell Engineering Laboratory, Aarhus University (Denmark). Luis attended Medical School at Oviedo University (Asturias, Spain) and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in immunology from the Autónoma University of Madrid (UAM) working on T cell development in the human thymus and spent four years at the Medical Research Council Centre for Protein Engineering (Cambridge, UK) where he worked with Robert E. Hawkins, Stephen J.

Luis Álvarez-Vallina

Associate Professor, Department of Molecular Engineering
Aarhus University

Luis Álvarez-Vallina, MD, PhD. Associate Professor at the Department of Engineering, Immunotherapy and Cell Engineering Laboratory, Aarhus University (Denmark). Luis attended Medical School at Oviedo University (Asturias, Spain) and completed a residency in Immunology at the Clínica Puerta de Hierro (Madrid). Luis earned a PhD in immunology from the Autónoma University of Madrid (UAM) working on T cell development in the human thymus and spent four years at the Medical Research Council Centre for Protein Engineering (Cambridge, UK) where he worked with Robert E. Hawkins, Stephen J.

 

Dr Katy Rezvani, MD

Chief of the Section for Cellular Therapy in the Department of Stem Cell Transplantation
MD Anderson

Dr. Katy Rezvani was recruited to MD Anderson in 2012 as Professor of Medicine, Director of Translational Research and Medical Director of the GMP Facility. She was appointed Chief of the Section for Cellular Therapy in the Department of Stem Cell Transplantation in 2017. She is the Principal Investigator on numerous grants and trials. Dr.

Dr Katy Rezvani, MD

Chief of the Section for Cellular Therapy in the Department of Stem Cell Transplantation
MD Anderson

Dr. Katy Rezvani was recruited to MD Anderson in 2012 as Professor of Medicine, Director of Translational Research and Medical Director of the GMP Facility. She was appointed Chief of the Section for Cellular Therapy in the Department of Stem Cell Transplantation in 2017. She is the Principal Investigator on numerous grants and trials. Dr.

 

Maria Themeli PhD- CCA

Assistant Professor
VUmc Cancer Center Amsterdam

Dr. Themeli studies cancer-fighting T cells, which may be genetically engineered with chimeric antigen receptors (CARs) or otherwise modified to augment their potency and persistence. She obtained her MD and PhD degrees from the University of Patras Medical School in Greece. During her postdoctoral studies, at MSKCC in Dr. Michel Sadelain’s lab, she focused her efforts on the use of induced Pluripotent Stem Cells (iPSC) to obtain mature, functional, antigen-specific T cells for cancer immunotherapy.

Maria Themeli PhD- CCA

Assistant Professor
VUmc Cancer Center Amsterdam

Dr. Themeli studies cancer-fighting T cells, which may be genetically engineered with chimeric antigen receptors (CARs) or otherwise modified to augment their potency and persistence. She obtained her MD and PhD degrees from the University of Patras Medical School in Greece. During her postdoctoral studies, at MSKCC in Dr. Michel Sadelain’s lab, she focused her efforts on the use of induced Pluripotent Stem Cells (iPSC) to obtain mature, functional, antigen-specific T cells for cancer immunotherapy.

 

Rachel Webster PhD

Decision Resources

Rachel Webster PhD

Decision Resources
 

Dr Sarah Snykers

QC Manager
Celyad

Sarah has over 10 years of experience in cell therapy, biomedical research and development.

Dr Sarah Snykers

QC Manager
Celyad

Sarah has over 10 years of experience in cell therapy, biomedical research and development.

 

Dr Zoltan Ivics

Head of Transposition and Genome Engineering
Paul Ehrlich Institute

Dr Zoltan Ivics

Head of Transposition and Genome Engineering
Paul Ehrlich Institute
 

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

Kim Nguyen, PhD

Director, CMC
Precision Biosciences

Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.

Resources

Download Resource

Event Partners

Media Partners

Become a Sponsor or Exhibitor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Mövenpick Hotel Berlin, Schöneberger Str. 3, 10963 Berlin, Germany

Movenpick Berlin, the venue for CAR-T Congress

Mövenpick Hotel Berlin is a 4-star hotel located in the city centre of Berlin near the Anhalter Bahnhof S-Bahn train station and Berlin’s famous public square, Potsdamer Platz. Book a room including buffet style breakfast for only €119.00 (based on single occupancy).

Book now
T: + 49 (0) 30 23 006 186 
E: [email protected]

Remember to always quote “KISACO RESEARCH LTD” when booking.

CONFERENCE PACKAGES

Register and pay by 17th November to take advantage of the Early Bird pricing below.

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: discounts cannot be combined.

Saturday, November 18, 2017 to Thursday, February 1, 2018
Pharma & Biopharma: 2 Day Conference
€1,299 + VAT
Standard Pricing
2 Day Conference
Refreshments, Breakfast & Lunch
All Networking & Social events
Saturday, November 18, 2017 to Thursday, February 1, 2018
Pharma & Biopharma: 2 Day Conference + Seminar
€1,599
Standard Pricing
2 Day Conference & Seminar
Refreshments, Breakfast & Lunch
All Networking & Social events
Evening Seminar
Thursday, August 31, 2017 to Thursday, February 1, 2018
Academics & Non-Profits: 2 Day Conference
€499 + VAT
Standard Pricing
2 Day Conference
Refreshments, Breakfast & Lunch
All Networking & Social events
Monday, October 2, 2017 to Thursday, February 1, 2018
Academics & Non-Profits: 2 Day Conference + Seminar
€799 + VAT
Standard Pricing
2 Day Conference & Seminar
Refreshments, Breakfast & Lunch
All Networking & Social events
Evening Seminar
Saturday, November 18, 2017 to Thursday, February 1, 2018
Vendors/ CROs/ Service Providers: 2 Day Conference
€1,599 + VAT
Standard Pricing
2 Day Conference
Refreshments, Breakfast & Lunch
All Networking & Social events
Saturday, November 18, 2017 to Thursday, February 1, 2018
Vendors/ CROs/ Service Providers: 2 Day Conference + Seminar
€1,899 + VAT
Standard Pricing
2 Day Conference & Seminar
Refreshments, Breakfast & Lunch
All Networking & Social events
Evening Seminar
Preparing registration...

Book a Team to Save More!

PLEASE NOTE: Team Discounts are only available for Industry Pricing
Book a Team of 3+
 - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for Combined CAR-T Congress Europe:

  • Please note that a €49 processing fee will apply to any invoices requested.
  • All Prices are in EUR and are exclusive of VAT @ 19%
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined with any other offer.
  • Please view our Cancellation Policy.
  • QUESTIONS? Please email [email protected].

Pass Features:

  • 2 Day conference pass
  • Networking Sessions
  • Lunch and Refreshments
  • Complimentary Articles and Content

CAR-T Congress USA

20th – 22nd March 2018

Boston | USA

More details coming soon...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us